IP Library Granted Patent US 12,447,130
Granted Patent B2
US 12,447,130 · App. 17/593,436 · Granted Oct 21, 2025

Capsules and capsule coatings for gastric residence dosage forms

Inventors: Nupura Bhise (Watertown, MA); Erick Peeke (Cambridge, MA); Marlene Schwarz (Auburndale, MA); Megan Bishoff (Boston, MA); Sonia Holar (Boston, MA); David Altreuter (Wayland, MA)
Assignee: LYNDRA THERAPEUTICS, INC.
A61K9/4891A61K9/485A61K9/4866
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,447,130
App. No.
17/593,436
Granted
Oct 21, 2025
Kind
B2
Abstract

Provided are gastric residence dosage forms comprising: a gastric residence system in a folded configuration; a capsule encapsulating the gastric residence system in a folded configuration; and a coating on the capsule, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration. The coating on the capsule includes a polymer, an anti-tacking agent, and/or a hydration aid.

Claims (28)

1. A gastric residence dosage form comprising:

a gastric residence system in a folded configuration;

a sleeve surrounding at least a portion of the gastric residence system in the folded configuration, wherein the sleeve is configured to bind the gastric residence system into the folded configuration;

a capsule encapsulating the gastric residence system in the folded configuration; and

a coating on the capsule,

wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.

2. The gastric residence dosage form of claim 1 , wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in a first amount of time when exposed to an aqueous pH 7.0 environment, and the first amount of time is greater than a second amount of time for the gastric residence dosage form to allow the gastric residence system to assume an open configuration when exposed to an aqueous pH 3.0 environment.

3. The gastric residence dosage form of claim 1 , wherein the coating comprises a reverse-enteric polymer.

4. The gastric residence dosage form of claim 3 , wherein the reverse-enteric polymer comprises a polymethacrylate-based polymer.

5. The gastric residence dosage form of claim 1 , wherein the coating comprises 3 to 25 wt. % anti-tacking agent.

6. The gastric residence dosage form of claim 1 , wherein the coating comprises from 1 to 20 wt. % plasticizer.

7. The gastric residence dosage form of claim 1 , wherein the coating comprises from 3 to 35 wt. % hydration aid.

8. The gastric residence dosage form of claim 1 , wherein the sleeve comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.

9. The gastric residence dosage form of claim 1 , wherein the gastric residence dosage form is used to treat a human.

10. The gastric residence dosage form of claim 1 , wherein the coating comprises from 50 to 95 wt. % reverse-enteric polymer.

11. The gastric residence dosage form of claim 1 , wherein the coating comprises an anti-tacking agent.

12. The gastric residence dosage form of claim 11 , wherein the anti-tacking agent comprises at least one of talc or magnesium stearate.

13. The gastric residence dosage form of claim 1 , wherein the coating comprises a plasticizer.

14. The gastric residence dosage form of claim 13 , wherein the plasticizer comprises at least one of a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.

15. The gastric residence dosage form of claim 1 , wherein the coating comprises a hydration aid.

16. The gastric residence dosage form of claim 15 , wherein the hydration aid comprises at least one of a polyvinylpyrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.

17. The gastric residence dosage form of claim 1 , wherein the capsule comprises at least one of gelatin, hydroxypropyl methylcellulose, or pullulan.

18. A method of making the gastric residence dosage form of claim 1 comprising:

binding the gastric residence system into the folded configuration with the sleeve;

encapsulating the gastric residence system in the folded configuration with the capsule; and

coating the capsule with a reverse-enteric coating to form the gastric residence dosage form.

19. The method of claim 18 , comprising binding the gastric residence system in the folded configuration with a sleeve prior to encapsulating.

20. The method of claim 18 , wherein coating the capsule with a reverse-enteric coating comprises pan-coating the capsule.

Assignments (6)
CHANGE OF NAME Recorded Nov 19, 2025
From: ISP ACQUISITION COMPANY, INC.
To: NORTIVA BIO, INC.
Reel/Frame 073607/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2025
From: LYNDRA THERAPEUTICS, INC.
To: ISP ACQUISITION COMPANY, INC.
Reel/Frame 073610/0424 →
RELEASE OF SECURITY INTEREST Recorded Dec 28, 2023
From: ISP HOLDINGS LLC
To: LYNDRA THERAPEUTICS, INC.
Reel/Frame 065970/0490 →
CONFIRMATORY LICENSE Recorded Dec 13, 2023
From: LYNDRA THERAPEUTICS, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065987/0860 →
SECURITY INTEREST Recorded Jul 13, 2022
From: LYNDRA THERAPEUTICS, INC.
To: ISP HOLDINGS LLC
Reel/Frame 060499/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: BHISE, NUPURA; PEEKE, ERICK; SCHWARZ, MARLENE; BISHOFF, MEGAN; HOLAR, SONIA; ALTREUTER, DAVID
To: LYNDRA THERAPEUTICS, INC.
Reel/Frame 058824/0012 →
Continuity (2)
Provisional Application 62821352 · Mar 20, 2019
Related Publication 20220160642A1 · May 26, 2022
References Cited (133)
US 6200603B1 · Rowe et al. · 2001 [cited by applicant]
US 9737905B2 · Byron et al. · 2017 [cited by applicant]
US 9827203B2 · Stella et al. · 2017 [cited by applicant]
US 10182985B2 · Bellinger et al. · 2019 [cited by applicant]
US 10413507B2 · Zhang et al. · 2019 [cited by applicant]
US 10517819B2 · Bellinger et al. · 2019 [cited by applicant]
US 10517820B2 · Bellinger · 2019 [cited by applicant]
US 10532027B2 · Bellinger · 2020 [cited by applicant]
US 10596110B2 · Bellinger · 2020 [cited by applicant]
US 10610482B2 · Bellinger · 2020 [cited by applicant]
US 10716751B2 · Bellinger et al. · 2020 [cited by applicant]
US 10716752B2 · Bellinger et al. · 2020 [cited by applicant]
US 10849853B2 · Bellinger et al. · 2020 [cited by applicant]
US 10953208B2 · Zhang et al. · 2021 [cited by applicant]
US 11077056B2 · Bellinger et al. · 2021 [cited by applicant]
US 11083690B2 · Zhang et al. · 2021 [cited by applicant]
US 11246829B2 · Bellinger et al. · 2022 [cited by applicant]
US 11357723B2 · Bellinger et al. · 2022 [cited by applicant]
US 11389399B2 · Bellinger et al. · 2022 [cited by applicant]
US 11576859B2 · Kanasty et al. · 2023 [cited by applicant]
US 11576866B2 · Bellinger et al. · 2023 [cited by applicant]
US 11793751B2 · Grant et al. · 2023 [cited by applicant]
US 11992552B2 · Bellinger · 2024 [cited by applicant]
US 12023406B2 · Kanasty · 2024 [cited by applicant]
US 12109305B2 · Bellinger · 2024 [cited by applicant]
US 12142158B2 · Kanasty · 2024 [cited by applicant]
US 20050064027A1 · Jacob et al. · 2005 [cited by applicant]
US 20060257484A1 · Hwang et al. · 2006 [cited by applicant]
US 20080206145A1 · Afargan · 2008 [cited by examiner]
US 20090304768A1 · Lapidot et al. · 2009 [cited by applicant]
US 20100064100A1 · Bains · 2010 [cited by applicant]
US 20110091542A1 · Navon · 2011 [cited by examiner]
US 20150366815A1 · Teles · 2015 [cited by applicant]
US 20160317796A1 · Zhang et al. · 2016 [cited by applicant]
US 20170106099A1 · Bellinger · 2017 [cited by applicant]
US 20170128576A1 · Zhang et al. · 2017 [cited by applicant]
US 20170135954A1 · Bellinger et al. · 2017 [cited by applicant]
US 20170266112A1 · Bellinger et al. · 2017 [cited by applicant]
US 20180311154A1 · Bellinger et al. · 2018 [cited by applicant]
US 20190000768A1 · Shimokawa · 2019 [cited by applicant]
US 20190070107A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190070108A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190070143A1 · Boulas et al. · 2019 [cited by applicant]
US 20190125667A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190133936A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190175500A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190231697A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190254966A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190262265A1 · Bellinger et al. · 2019 [cited by applicant]
US 20190298652A1 · Bellinger et al. · 2019 [cited by applicant]
US 20200030234A1 · Zhang et al. · 2020 [cited by applicant]
US 20200085736A1 · Bellinger et al. · 2020 [cited by applicant]
US 20200085737A1 · Bellinger et al. · 2020 [cited by applicant]
US 20200146979A1 · Kanasty · 2020 [cited by applicant]
US 20200281851A1 · Grant et al. · 2020 [cited by applicant]
US 20210093564A1 · Bellinger et al. · 2021 [cited by applicant]
US 20210113460A1 · Bellinger et al. · 2021 [cited by applicant]
US 20210128460A1 · Bellinger et al. · 2021 [cited by applicant]
US 20210177750A1 · Bellinger et al. · 2021 [cited by applicant]
US 20210196627A1 · Grant et al. · 2021 [cited by applicant]
US 20220093006A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220192995A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220387310A1 · Altreuter et al. · 2022 [cited by applicant]
US 20220387311A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220387312A1 · Kanasty et al. · 2022 [cited by applicant]
US 20220409528A1 · Kanasty et al. · 2022 [cited by applicant]
US 20230039421A1 · Bellinger et al. · 2023 [cited by applicant]
US 20230190941A1 · Montezco et al. · 2023 [cited by applicant]
US 20240139102A1 · Grant · 2024 [cited by applicant]
US 20240252483A1 · Bhise · 2024 [cited by applicant]
US 20240335400A1 · Beguin · 2024 [cited by applicant]
US 20240342081A1 · Bellinger · 2024 [cited by applicant]
US 20240382418A1 · Kanasty · 2024 [cited by applicant]
US 20240390270A1 · Kanasty · 2024 [cited by applicant]
US 20240398701A1 · Kanasty · 2024 [cited by applicant]
US 20240423909A1 · Bellinger · 2024 [cited by applicant]
CN 102300463A · 2011 [cited by applicant]
JP 2006508021A · 2006 [cited by applicant]
JP 2007145756A · 2007 [cited by applicant]
JP 2009523175A · 2009 [cited by applicant]
JP 2012500230A · 2012 [cited by applicant]
JP 2012510987A · 2012 [cited by applicant]
JP 2013129669A · 2013 [cited by applicant]
JP 2017518308A · 2017 [cited by applicant]
JP 2017524662A · 2017 [cited by applicant]
JP 2018517735A · 2018 [cited by applicant]
NO 2020191231A1 · 2020 [cited by applicant]
WO 2003082204A2 · 2003 [cited by applicant]
WO 2007002518A1 · 2007 [cited by applicant]
WO 2007083309A2 · 2007 [cited by applicant]
WO 2007084818A2 · 2007 [cited by applicant]
WO 2010064100A1 · 2010 [cited by applicant]
WO 2010064139A2 · 2010 [cited by applicant]
WO 2010128495A1 · 2010 [cited by applicant]
WO 2011048494A2 · 2011 [cited by applicant]
WO 2015187746A1 · 2015 [cited by applicant]
WO 2015191920A1 · 2015 [cited by applicant]
WO 2015191922A1 · 2015 [cited by applicant]
WO 2015191925A1 · 2015 [cited by applicant]
WO 2016178971A1 · 2016 [cited by applicant]
WO 2016205270A1 · 2016 [cited by applicant]
WO 2017022248A1 · 2017 [cited by applicant]
WO 2017070612A1 · 2017 [cited by applicant]
WO 2017100367A1 · 2017 [cited by applicant]
WO 2017205844A2 · 2017 [cited by applicant]
WO 2017205844A3 · 2018 [cited by applicant]
WO 2018064630A1 · 2018 [cited by applicant]
WO 2018102799A1 · 2018 [cited by applicant]
WO 2018227147A1 · 2018 [cited by applicant]
WO 2019060458A1 · 2019 [cited by applicant]
WO 2020036972A1 · 2020 [cited by applicant]
WO 2020117855A1 · 2020 [cited by applicant]
WO 2020191229A1 · 2020 [cited by applicant]
WO 2021092483A1 · 2021 [cited by applicant]
WO 2021092484A1 · 2021 [cited by applicant]
WO 2021092486A1 · 2021 [cited by applicant]
WO 2021092487A1 · 2021 [cited by applicant]
WO 2021092491A1 · 2021 [cited by applicant]
WO 2022159529A1 · 2022 [cited by applicant]
WO 2022236288A1 · 2022 [cited by applicant]
WO 2022236289A1 · 2022 [cited by applicant]
WO 2023141524A2 · 2023 [cited by applicant]
WO 2024031023A2 · 2024 [cited by applicant]
WO 2024073752A2 · 2024 [cited by applicant]
WO 2024249946A2 · 2024 [cited by applicant]
Extended European Search Report, dated Dec. 13, 2022, for European Patent Application No. 20773419.5, 9 pages. [cited by applicant]
Partial Supplementary Search Reports, dated Mar. 29, 2023, for European Patent Application No. 20774505.0, 12 pages. [cited by applicant]
International Preliminary Report on Patentability, issued Sep. 16, 2021, for PCT Application No. PCT/US2020/023704, filed Mar. 19, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Jun. 3, 2020, for PCT Application No. PCT/US2020/0023710, filed Mar. 19, 2020, 10 pages. [cited by applicant]
International Preliminary Report on Patentability, issued Sep. 16, 2021, for PCT Application No. PCT/US2020/0023710, filed Mar. 19, 2020, 7 pages. [cited by applicant]
International Search Report and Written Opinion, mailed May 27, 2020, for PCT Application No. PCT/US2020/023704, iled Mar. 19, 2020, 11 pages. [cited by applicant]
Hu, Y. (Feb. 28, 2013). Pharmaceutical Formulations 2nd Edition, China Medical Science and Technology Press: Bejing, pp. 172-173, 15 pages. [English Machine Translation]. [cited by applicant]
Li, H. et al. (2006). Coated Pharmaceutical Dosage Forms, China Pharmaceutical Science and Technology Press, pp. 109-111. [English Translation: Bauer, K.H. et al. (1998). “Biopharmaceutical Aspects,” Chapter 5 in Coated… [cited by applicant]